Tricida 'foreshadowed' its CRL — but shares still fall with fear of years-long delay
Nobody likes rejections. But it does help to have a heads-up.
Such is the case at Tricida, which was slapped with a complete response letter as regulators turned down its lead and only drug for metabolic acidosis in patients with chronic kidney disease.
“The CRL was not surprising as it was foreshadowed by an announcement in mid-July that the FDA has identified deficiencies in veverimer’s application,” Cowen’s Phil Nadeau wrote.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
